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a  b  s  t  r  a  c  t
This paper  explores  the  possibilities  of  making  meaningful  comparisons  of  the  veterinary
use  of antimicrobial  agents  among  countries,  based  on national  total  sales  data. Veterinary
antimicrobial  sales  data  on  country  level  and  animal  census  data  in  both  Denmark  and  the
Netherlands  were  combined  with  information  about  estimated  average  dosages,  to  make
model calculations  of the  average  number  of treatment  days  per  average  animal  per  year,
at  ﬁrst  based  on  the  assumption  that  the  treatment  incidence  is  the  same  in all  species
and  production  types.  Secondly,  the  exposure  in respectively  animals  for meat  production
and dairy  and  other  cattle  (excluding  veal  and  young  beef)  was  estimated,  assuming  zero
use in  the  dairy and  other cattle,  and  thirdly  by  assuming  respectively  100%  oral  and  100%
parenteral  administration.  Subsequently,  the  outcomes  of  these  model  calculations  were
compared  with  treatment  incidences  calculated  from  detailed  use  data  per  animal  species
from  the  national  surveillance  programmes  in  these  two  countries,  to  assess  their  accuracy
and relevancy.
In Denmark  and  in the  Netherlands,  although  the  computed  antimicrobial  exposure
would  seem  to be a reasonable  estimation  of  the  exposure  for all animals  as a whole,  it
differs  signiﬁcantly  from  the  measured  exposure  for most  species.  The  differences  in expo-
sure among  animal  species  were  much  higher  than  the  overall  difference  between  the  two
countries.  For  example,  the overall  model  estimate  of  9 treatment  days  per  year  for Denmark
is  a severe  overestimation  of  the  true  use in  poultry  (i.e.  3  days),  and  the overall  model  esti-
mate  of  13  treatment  days  per  year  for the  Netherlands  is  a severe  underestimation  of the
true use  in  veal  calves  (i.e.  66  days).
The conclusion  is that simple  country  comparisons,  based  on  total  sales  ﬁgures,  entail
the risk  of  serious  misinterpretations,  especially  if expressed  in  mg  per  kg.  The  use  of  more
precise  model  calculations  for making  such  comparisons,  taking  into  account  differences
in dosages  and  in  farm  animal  demographics,  only  slightly  reduces  this  risk.  Overall  model
estimates are  strongly  inﬂuenced  by animal  demographics  and  a  very  inaccurate  indication
of the true  differences  in  exposure,  per  animal  species.  To get  an  appropriate  certainty  about
the  true  differences  in  antimicrobial  exposure  between  countries  it is an  absolute  necessity
to have  reliable  information  about  the  use  per  animal  species.
© 2012 Elsevier B.V. All rights reserved.
∗ Corresponding author. Tel.: +31 317 48 45 59; fax: +31 317 48 44 90.
E-mail address: Nico.Bondt@wur.nl (N. Bondt).
1. Introduction
Antimicrobial exposure is considered an important
risk factor for emerging antimicrobial resistance which
poses risk to human health (Gould and MacKenzie, 2002).
0167-5877/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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Because of the effects of antimicrobial use in food ani-
mals on antimicrobial exposure and consequently the risk
of development of antimicrobial resistance, it is impor-
tant to gain quantitative insight into the use of veterinary
antimicrobial agents (Mevius et al., 1999). Some European
countries already have developed or are developing sophis-
ticated surveillance systems. The European Medicines
Agency (EMA) is currently carrying out a project called
European Surveillance of Veterinary Antimicrobial Use
(ESVAC), for a standardized collection of data on sales of
veterinary antimicrobial agents in Europe (EMA, 2011). The
ESVAC project was launched in September 2009; the terms
of reference included a request to develop a harmonized
approach for the collection and reporting of data on the
use of antimicrobial agents in animals from the EU Member
States.
An initial goal of the ESVAC project is to gain insight into
the use per country and the trends both on country level
and EU level and one of the intended uses of the collected
data is to aid interpretation of patterns and trends regard-
ing antimicrobial resistance. The data on country level
will undoubtedly also be used for making international
comparisons among countries, including comparisons with
overall antimicrobial and antimicrobial resistance in speci-
ﬁed species. Although dedicated drug monitoring systems,
on species level or even on farm level, are needed to assess
the true use levels of antimicrobial agents, it is expected
that for most countries in the coming years knowledge
about antimicrobial use will be primarily based on national
total sales data.
There is not yet a scientiﬁcally sound, generally
accepted and easily applicable method for performing
country comparisons of veterinary antimicrobial use.
Recent papers express the use in milligram (mg) of active
substance sold per kg meat produced and/or kg live ani-
mal  present (Ungemach et al., 2006; Grave et al., 2010;
EMA, 2011), which is fairly easy attainable but seems to be
a very rough indicator. The calculated differences in “mg
per kg” (whether live biomass, slaughtered weight, or a
mixture of these as in the “population correction factor”
(PCU)1) will probably be interpreted as differences in the
level of antimicrobial exposure. However, the use differs
signiﬁcantly among different species (Bondt et al., 2011;
DANMAP, 2011), and the effect of different animal demo-
graphics among countries on the total national use may be
high: some countries have relatively large pig or poultry
populations, while other countries have in the main exten-
sively held animals like dairy cows, beef cattle (suckling)
and sheep; it has not yet been determined whether aver-
age country levels of antimicrobial use might be an accurate
indicator for the true use levels in the different subsectors
of the animal population.
Furthermore, the differences in “mg  per kg” among
countries may  also reﬂect application of different phar-
macotherapeutic groups with signiﬁcant differences in
potency, hence differences in dosage.
1 EMA (2011) introduced the PCU, which is purely a technical unit of
measurement. A PCU is a kg of different categories of livestock and slaugh-
tered animals.
For international comparison, an alternative method is
therefore needed in the coming years, because in most
countries basically only total sales ﬁgures will be available.
This article explores the possibilities of making meaningful
comparisons of the veterinary use of antimicrobial agents
among countries, based on total sales data, by assessing the
accuracy of three different model calculations for the com-
parison of antimicrobial exposure in Denmark (DK) and
the Netherlands (NL). As both countries have reasonably
accurate use data on animal species and production type
level, the outcomes of the model calculations based on total
sales data will be compared with the measured use data per
species. Our research questions were as follows:
- Are national total sales data suitable for making
meaningful country comparisons of veterinary use of
antimicrobials?
- What is the accuracy of the outcomes of the model cal-
culations, based on total sales data, i.e. can these models
substitute national drug monitoring systems on species
level?
- What will be the more adequate model to quantify the
use of antimicrobials for country comparisons?
2. Materials and methods
Quantifying antimicrobial exposure requires informa-
tion about the amount and potency of active substances
used in a certain time period, and animal population data.
The level of exposure (E) could for example be expressed
as the amount of active substance used (X, expressed in
mg)  per animal body weight (Y, expressed in kg live body
weight) per year, i.e. E = X/Y. However, this expression is
inadequate due to at least two complications. The ﬁrst
complication concerns the quantity X: one mg  of active sub-
stance in one country is not equivalent to one mg  of active
substance in another, due to differences in patterns of use
(choice and dosing of used antimicrobial agents) and hence
differences in average potency and in average dosage. The
second complication concerns the quality of Y: one kg of
animal in one country differs from 1 kg of animal in another,
due to substantial differences in animal demographics.
In view of these complications, the Animal Deﬁned
Daily Dose (abbreviated ADD, used to designate the DDD
for animals) was introduced, which is the deﬁned aver-
age maintenance dose of a speciﬁed medicine per kg of
a speciﬁed animal per day, applied for its main indication
(Jensen et al., 2004; Chauvin et al., 2008). The ADD depends
on species and may  also differ among countries. The ideal
method for gaining insight into the true exposure to antimi-
crobial agents is to calculate the number of ADDs (NADD)
used per animal per year as applied in human pharmaco-
epidemiology with the number of Deﬁned Daily Dosages
(DDD) per 1000 inhabitant-days (WHO, 2012). NADD rep-
resents the treatment days. Because animal body weight
and dosage is highly variable per species, NADD calculated
per animal species is a more appropriate measure in vet-
erinary pharmacology.
Calculating NADD requires detailed information about
the amount of individual active substances or even indi-
vidual medicines used per animal species. Such detailed
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Table  1
Total sales of veterinary antimicrobial agents in the Netherlands and Denmark in 2010, in tonnes of active substance and in percentage of total sales
(including use in minor species).
Pharmacotherapeutic group Netherlands Denmark
Intestinal antiinfectivesa 10f 2% 1 1%
Tetracyclines 217 50% 36 28%
Oxytetracycline 140 32% 6 4%
Doxycycline 75 17% 20 16%
other  tetracyclines 2 0% 10 8%
Amphenicolse 2f 1% 1 1%
Penicillins 66g 15% 38 30%
Narrow spectrum penicillinsb 7f 2% 37 29%
Other  penicillinse 59 14% 1 1%
1st  and 2nd generation cephalosporinsc 0.3 0% 0.4 0%
3rd  and 4th generation cephalosporins 0.7 0% 0.1 0%
Trimethoprim/sulfonamides 78 18% 15 12%
Macrolides 37f 8% 14 11%
Fluoroquinolones 2 0% 0 0%
Other  quinolones 5 1% 1 1%
Others  (e.g. pleuromutilins)d 1f 0% 11 8%
Combinationse 14f 3% 11 9%
Total 433 100% 127 100%
Sources: FIDIN (2012),  Bondt et al. (2011), DANMAP, 2011.
a Intestinal anti-infectives comprise aminoglycosides (almost 100% orally administered) and orally administered colistin.
b Narrow spectrum penicillins comprise beta-lactamase sensitive and resistant penicillins (ATC Vet code QJ01CE and QJ01CF).
c In Denmark ﬁrst and second generation cephalosporins are only used in pets (majority) and intramammary, in the Netherlands mostly for food producing
animals (intramammary).
d Others comprise pleuromutilins and polymyxins, excluding orally administered colistin.
e All antibacterials usually used in combination, like lincosamides/spectinomycin, streptomycin in combination (combined with betalactamase sensitive
penicillin, which is usually used alone, and therefore is noted in a separate row).
f Quantity of sales estimated based on farms in MARAN sample survey (Bondt et al., 2011).
g Part of the sales of penicillins is included in ‘Combinations’.
information is available in the Danish Vetstat database
(DANMAP, 2011) and in the Dutch sample survey (Bondt
et al., 2011), but not in most other countries. Table 1 shows
the total sales ﬁgures for Denmark (DANMAP, 2011) and the
Netherlands (Bondt et al., 2011). National sales ﬁgures only
comprise the total sales per group of antimicrobial agents,
without being further speciﬁed per species.
To estimate the exposure to veterinary antimicrobial
agents using sales data, the total amount of antimicrobial
agents sold in a certain country in a certain year (S) must be
related to the size of the farm animal population (P). In this
study, only the major animal species cattle, pigs and poul-
try were included. Minor species like sheep, fur animals
and farmed ﬁsh were not included, nor were horses and
other companion animals. The expression of S must take
into account the differences in dosages (i.e. ADDs) and the
expression of P must take into account the demographic
features of the animal population.
Suppose there are I types of antimicrobial agents sold
in a country with J categories of animals (species and pro-
duction type). To explore the possible methods, following
notations are used:
i: denotes an antimicrobial agent sold in a certain country,
i = 1, 2, . . .,  I;
j: denotes a category of animals present in the country,
j = 1, 2, . . .,  J;
Dij: denotes the ADD of antimicrobial agent i for animal
category j, measured in mg  per kg per 24 h;
Si: denotes the amount of antimicrobial agent i sold in a
certain year and country in tonnes;
Sj: denotes the total amount of antimicrobial agents sold
in a certain year and country in animal category j;
Sij: denotes the amount of antimicrobial agent i sold/used
for animals in the category j in tonnes;
Tj: denotes the total live weight of farm animals in cate-
gory j being treated with antimicrobials in a certain year,
according to their standard dosages;
Tij: denotes the total live weight of farm animals in cate-
gory j being treated with antimicrobial agent i according
to the standard dosage;
Wj: denotes the average live treatment weight of the ani-
mals in kg in category j;
Nj: denotes the numbers of farm animals in category j
averagely present in a certain year;
NADDij: denotes the number of daily doses from antimi-
crobial agent i an average farm animal in category j
received for in a certain year, according to the standard
dosage;
NADDj: denotes the number of daily doses from all antimi-
crobial agents, which an average farm animal in category
j received, in a certain year, according to their standard
dosages;
NADD: denotes the number of daily doses from all antimi-
crobial agents an average animal of all categories received,
in a certain year, according to their standard dosages.
All variables denote the values for a certain time frame,
in this case one year. Theoretically, when information about
Sij is available, Tij can be calculated as Sij/Dij and NADDij can
be calculated as the total biomass in animal category j being
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treated with antimicrobial i divided by the total treatable
live weight (population at risk), i.e.
NADDij =
Tij
WjNj
= Sij
DijWjNj
, (1a)
where the total treatable live weight of animals in category
j is calculated as WjNj. This is the ideal information about
exposure to antimicrobial agents in different animal cate-
gories, based on use/sales data per species. The exposure
in animal category j to all antimicrobial agents, NADDj, can
then be calculated as:
NADDij =
∑I
i=1Tij
WjNj
(1b)
And the exposure for all animal species as a whole can be
calculated as the weight-weighted average of the exposure
for the different animal categories:
NADD =
∑J
J=1NADDjWjNj∑J
J=1WjNj
(1c)
In practice, however, the information about the
use/sales per species (Sij) is not available in most countries.
Alternative methods should therefore be used to assess
NADDj and NADD with additional parameters. The pro-
posed method calculates the following parameters:
- the average dosage for antimicrobial agent i (denoted as
D¯i) for the whole animal population, which is calculated
as the weight-weighted average of the ADDs for different
animal categories, i.e.:
D¯i =
∑J
J=1DijWjNj∑J
J=1WjNj
. (2a)
The average dosage D¯i depends therefore on the ADDs
for the individual species and the proportion of biomass
for each species in the total population. The dosage D¯i
represents the average amount of antimicrobial agent i
(in milligrams) required to treat one kilogram of the mean
national animal during one day, and can best be described
as an overall ‘potency indicator’.
- the average treatment weight of the animal category j
(denoted as W¯j) in the population ‘at risk’ of being treated
with antimicrobial agents in a certain year. The average
treatment weights per head (kg) are estimated as follows
(Jensen et al., 2004): cows/bulls 600, heifers 300, young
cattle for veal and beef production 86 (Bondt et al., 2011),
female calves < 12 months 86,2 breeding pigs 200, piglets
(below 20 kg) 10, fattening pigs 50, turkeys 6, broilers 1.0,
other poultry 1.0.3 The total treatable weight (denoted as
W¯) is then calculated by summing up the weights in all
2 Treatment weight of female calves is assumed to be equal to that of
calves for veal and beef production.
3 For Gallus gallus, all animals were calculated with an average weight
of 1.0 kg, which is slightly below the actual live adult weight of parent
and grandparent ﬂocks of broilers and laying hens. The number of laying
hens were used only to calculate the amount of “other poultry”; for The
Netherlands this number comes from Dutch national census data (CBS)
and for Denmark it was  estimated on the basis of egg production ﬁgures.
the categories, i.e.
W¯ =
J∑
J=1
W¯jNj. (2b)
In general, we use census data to determine the number
of animals in different categories. For the number of poul-
try no census data from the Eurostat database (Eurostat,
2012) were available, therefore farm census data of FAO
(FAO, 2012) were used. Laying hens were excluded, as
these animals will not or very scarcely be treated with
antimicrobial agents during egg production.
- the total biomass being treated with antimicrobial agent i
(denoted as Ti), which is estimated as: T¯i = Si/D¯i. The total
amount of biomass being treated (T) with all antimicro-
bial agents is then estimated as:
T¯ =
I∑
i=1
T¯i. (2c)
With these parameters, the estimator for the true level
of exposure to all production animals as a whole (denoted
as

NADD)  is deﬁned as:

NADD = T
W¯
. (2d)
When the true exposure NADD and NADDj is known
from collected use data on species level, a simple accuracy
measure ε can be deﬁned for the estimator

NADD.  The accu-
racy measures ε represent the error percentage of the esti-
mated exposure to the true exposure. The more accurate
an estimator is, the closer the percentage will be to zero.
ε =
( 
NADD
NADD
− 1
)
× 100%. (3a)
We consider an estimator reasonably accurate when the
absolute value of the error percentage is smaller than 30%.
To apply the method described above, assumptions
need to be made concerning the categories of animals
receiving their shares of the total sales of antimicrobial
agents (i.e. Sj). At ﬁrst, a general assumption in the esti-
mation of an average dosage (overall ‘potency indicator’) is
that all animal categories get an equal exposure to antimi-
crobial agents, which is deﬁnitely not true. On the contrary,
it is common knowledge that certain categories of the farm
animals only get limited amounts of antimicrobial agents,
for example grown cattle.
Using the calculation method and assumptions
described above, the following outcomes for Expo-
sure (E) are possible, all expressed in an estimated number
of daily doses or treatment days per biomass year (

NADD):
A. Total sales (tonnes) divided by the total live treatment
weight of the livestock and an overall average dosage
(EA).
B. Total sales (tonnes) divided by the live treatment weight
of only animals for meat production and the average
dosage for those animals (EB).
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C. Two estimates, i.e. one for each subpopulation, ﬁrstly
meat animals (pigs, calves for veal and young beef pro-
duction, poultry except laying hens), secondly dairy and
other cattle.
a. The total estimated sales (tonnes) orally adminis-
tered, divided by the live treatment weight of animals
for meat production and the average dosage for that
category of animals (EC oral).
b. The total estimated sales parenterally administered,
divided by the live treatment weight of the dairy and
other cattle, and the average dosage for that category
of animals (EC parental).
To assess the accuracy and relevancy of the outcomes
of the three model calculations, the true levels of expo-
sure (i.e. NADDj) for the Netherlands and for Denmark
were determined using collected data on species level from
Vetstat and the Dutch sample survey. For each species
and type of antimicrobial agent the used quantity was
divided by the treatable weight, and the estimated aver-
age dosage. Exactly the same approach was followed as in
the three model calculations, however, this time based on
collected use data per species, instead of total sales data.4
The use in minor species was excluded, which is 11% of the
total sales in Denmark (mainly fur animals, ﬁsh, and com-
panion animals) and an estimated 5% in the Netherlands
(van Geijlswijk et al., 2011; FIDIN, 2012). The 2010 data
for Denmark are extracted from the VetStat database in
February 2012 and therefore might deviate slightly from
the data as published in the DANMAP 2010 report. In
the Netherlands, a yearly sample survey is carried out on
approximately 400 farms, in which the antimicrobial use
is determined on a detailed level. The actual use in the
Netherlands might differ from the quantities, as measured
in the sample survey. Denmark has the Vetstat system,
which covers 100% of the farms.
In the Netherlands and Denmark every authorized
medicine is assigned a dedicated ADD. The ADD is deter-
mined by the administration route and often also the
species, e.g. with in many cases much higher doses used for
poultry. The applied ADDs in this research are a compro-
mise based on a review of the available information in the
Dutch sample survey and the Danish Vetstat system, thus
including doses applied in Denmark and the Netherlands.5
3. Results
Table 2 shows the estimated average dosages (i.e. D¯i)
per antimicrobial group calculated as described before
4 For sows/piglets the use of sows, piglets and weaners is included, and
the weight at treatment of piglets with a live weight of less than 20 kg plus
breeding pigs (see Table 3). The use level of fattening pigs is calculated
using the weight of fattening pigs of at least 20 kg as denominator (see
Table 3). For veal and young beef in Denmark the nominator comprises
the  use of all calves, whereas the weight of only the male animals for veal
and young beef production was used as denominator. Therefore in Fig. 2
the NADD for veal and young beef in Denmark will be a maximum value.
5 As the WHO  Collaborating Centre for Drug Statistics Methodology
states on their website (www.whocc.no), the deﬁned daily dose, in this
paper ‘ADD’, “is sometimes a dose that is rarely if ever prescribed, because
it  is an average of two or more commonly used dose sizes”.
Table 2
Estimated average dosage per group of antibacterial agents for NL and DK,
expressed in mg per kg live weight per day (ADDkg).
Admin.
routea
Cattle Poultry Pigs
Intestinal anti-infectives o 10 10 10
Oxytetracycline o 35 65 30
Oxytetracycline p 7 7
Doxytetracycline o 10 15 10
Other tetracyclines o 3 25
Amphenicols o 20 10
Amphenicols p 15 10
Narrow spectrum penicillins o 17
Narrow spectrum penicillins p 13 13
Other penicillins o 35 25 15
Other penicillins p 10 10
Cephalosporins 1/2 gen o 1
Cephalosporins 3/4 gen p 1 2
Trimethoprim/sulfonamides o 35 60 27
Trimethoprim/sulfonamides p 16 16
Macrolides o 25 60 13
Macrolides p 2 2
Fluoroquinolones o 3 10
Fluoroquinolones p 4 3
Other quinolones o 18 11 20
Others (e.g. pleuromutilins) o, p 10 10
Combinations o 10 140 9
Combinations p 15 15
Combinations im 1
a Administration routes: oral (o), parenteral (p), intra-mammary (im).
(parameter (2a)). The dosages in Table 2 represent the
average number of milligrams of a certain group of active
substances required to treat one kilogram of animal in one
day. The table shows the large differences in dosage among
species and also illustrates the fact that most antimicrobial
agents are administered orally.
Table 3 shows the size of the major livestock species
(cattle, pigs, poultry) in both countries, and the estimated
average weights during treatment.
Table 4 shows the use for the Netherlands, expressed in
tonnes, based on the total sales data combined with the
shares per species, antimicrobial group and administra-
tion route from the sample survey. Table 5 shows the use
for Denmark, extracted from the Vetstat database. It was
roughly estimated that in the Netherlands and Denmark
respectively half and two-thirds of the sales of combina-
tions comprise intramammaries.
Fig. 1 shows the outcomes of the three different model
calculations based on total sales data, expressed in number
of daily doses or treatment days per biomass year (NADD).
For these calculations the data from Tables 1 (total sales,
including the use in minor species), 2 and 3 were used.
Fig. 2 shows the best possible estimates of the true expo-
sure to antimicrobial agents in 2010, based on the collected
use data per species from DANMAP-2010 and MARAN, as
presented in Tables 4 and 5 (Bondt et al., 2011; DANMAP,
2011).
Fig. 2 reveals the large differences in antimicrobial expo-
sure among species.
Table 6 indicates the accuracy of the outcomes of the
three different model calculations (Fig. 1), based on the
percentual error of the true exposure (Fig. 2).
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Table 3
Animal demographics in the Netherlands and Denmark in 2010 and estimated treatment weights; percentage of total weight in brackets.
Number of animals
(in 1000s)a
Estimated average
treatment weightb
Total treatment weight
of animals (in
1000 tonnes)
The Netherlands Denmark The Netherlands Denmark
Total of cattle population Cat. 3960 1630 1381 (68%) 599 (48%)
Bovine  animals aged between 1 and 2
years: Female
B 560 284 300 168 85
Bovine  animals aged between 1 and 2
years: Male
A 56 34 300 17 10
Bovines animals of 2 years and over:
Female
B 1747 748 600 1048 449
Bovines animals of 2 years and over:
Male
B 20 12 600 12 7
Calves  for slaughter A 921 6 86 79 1
Other  calves: Female B 580 266 86 50 23
Other  calves: Male A 77 281 86 7 24
Weight  veal and young beef production A 103 (5%) 35 (3%)
Weight dairy and other cattle B 1278 (63%) 564 (45%)
Total  of the pig population 12,206 12,293 590 (29%) 643 (51%)
Piglets  with a live weight of less than
20 kg
A 4649 4146 10 46 41
Pigs  with a live weight between 20 and
50 kg
A 2031 3469
Fattening pigs between 50 and 80 kg A 2111 2699
Fattening pigs between 80 and 110 kg A 1919 675
Fattening pigs of at least 110 kg A 388 7
Fattening pigs of at least 20 kg 6449 6850 50 322 343
Breeding pigs with a live weight of
50 kg and higherc
A 1107 1297 200 221 259
Poultry (×1000 animals) 61 (3%) 10 (1%)
Turkeys A 1167 201 6.0 7 1
Other  poultry, excluding layers A 54,367 8323 1.0 54 8
Total  of the whole livestock population 2032 (100%) 1252 (100%)
Total of category A: animals for meat
production
A 754 (37%) 688 (55%)
Total  of category B: dairy and other
cattle
B 1278 (63%) 564 (45%)
a Eurostat (2012).
b Jensen et al. (2004), Bondt et al. (2011).
c Breeding pigs comprises mainly sows, but also includes growing gilts above 50 kg. Therefore the estimated average weight is below the average adult
weight of sows.
4. Discussion
4.1. Estimated differences
The true average NADD6 for all animals will be approx-
imately 13 for the Netherlands and 9 for Denmark, based
on the use data per species. This outcome indicates that
the average use for all animals of major species in the
Netherlands is approximately 40% higher than the over-
all average use in Denmark. This result is similar to model
calculation EA. The overall average NADD is mainly deter-
mined by the differences in the largest animal categories,
i.e. pigs and cattle. In most countries a large use in poul-
try will play a minor role in the overall average, because
of the limited size of this subsector, not in numbers but in
biomass. In terms of risk assessment, a high use in poultry
6 The average exposure for all animals was calculated as the weighted
average of the antimicrobial exposure calculated per animal species. The
total treatable weight of the corresponding animal species, as shown in
Table 3, was  used as the weighting factor.
may  be very relevant, but an overall average use level will
not reveal such information.
The use data per species reveal that the antimicrobial
use in pigs (total) in the Netherlands was  35% higher than in
Denmark. The differences in use in sows/piglets and fatten-
ing pigs might be due to the fact that in Denmark the use in
pigs between 25 and 30 kg is ascribed to sows/piglets, and
in the Netherlands to fattening pigs, which complicates a
distinct comparison. Besides, the use level for sows/piglets
is an average of the use in respectively sows and piglets,
and will probably be an overestimation of the true use in
sows and a serious underestimation of the true use level
in piglets (Bondt et al., 2011). The use in dairy and other
cattle appears to be relatively low, in both countries. The
most remarkable difference between NL and DK is the large
production of veal and young beef in the Netherlands, with
a high antimicrobial use. Another striking difference is the
very low use level in poultry in Denmark, compared to the
Netherlands.
The calculated error percentages show that an over-
all national average of NADD is unsuitable to indicate the
true levels of exposure, in the different animal species.
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Table  4
Antibiotic use per species in the Netherlands in 2010, per group of antimicrobials, administration route and species in tonnes, based on use data in Dutch
sample survey.
Adm. route Total Cattle Veal calves and
young beef
Poultry Pigs Fattening
pigs
Sows,
piglets
Intestinal anti-infectives o 9.50 0.44 5.79 1.99 1.28 0.19 1.09
Oxytetracycline o 130.59 1.51 78.11 1.13 49.83 15.43 34.41
Oxytetracycline p 2.13 1.45 0.00 0.00 0.68 0.40 0.28
Doxytetracycline o 71.53 0.56 14.16 8.70 48.10 33.11 14.99
Other  tetracyclines o 1.50 0.99 0.50 0.00 0.00 0.00 0.00
Amphenicols o 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amphenicols p 2.19 0.52 1.43 0.00 0.23 0.20 0.04
Narrow spectrum penicillins o 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Narrow spectrum penicillins p 6.97 3.62 0.07 0.97 2.31 0.52 1.80
Other  penicillins o 48.94 0.25 27.90 10.61 10.19 1.81 8.38
Other  penicillins p 7.05 2.90 0.34 0.00 3.81 1.11 2.71
Cephalosporins 1/2 gen o 0.25 0.25 0.00 0.00 0.00 0.00 0.00
Cephalosporins 3/4 gen p 0.70 0.64 0.03 0.00 0.03 0.00 0.03
Trimethoprim/sulfonamides o 66.20 0.93 23.15 9.91 32.21 11.99 20.22
Trimethoprim/sulfonamides p 8.01 6.48 0.04 0.00 1.49 0.20 1.29
Macrolides o 33.79 0.00 10.12 3.09 20.58 17.48 3.10
Macrolides p 1.07 0.64 0.19 0.00 0.24 0.10 0.15
Fluoroquinolones o 0.79 0.55 0.15 0.03 0.05 0.01 0.04
Fluoroquinolones p 0.79 0.55 0.15 0.03 0.05 0.01 0.04
Other  quinolones o 4.47 0.19 0.63 3.61 0.04 0.01 0.03
Others  (e.g. pleuromutilins) o, p 1.24 0.00 0.00 0.00 1.24 0.55 0.68
Combinations o 3.04 0.09 0.00 2.67 0.28 0.09 0.19
Combinations p 10.64 7.36 1.23 0.00 2.04 0.40 1.65
Total 411.37 29.93 163.99 42.74 174.70 83.60 91.11
Table 5
Antibiotic use per species in Denmark in 2010, per group of antimicrobials, administration route and species in tonnes, based on use data in Vetstat database.
Adm. route Total Cattle Veal calves and
young beef
Poultrya Pigs Fattening
pigsb
Sows,
pigletsb
Intestinal anti-infectives o 1.19 0.02 0.18 0.00 0.99 0.02 0.98
Oxytetracycline o 0.06 0.00 0.01 0.00 0.04 0.01 0.03
Oxytetracycline p 5.25 1.26 0.48 0.00 3.50 1.31 2.20
Doxytetracycline o 18.86 0.00 0.00 0.23 18.63 6.79 11.83
Other  tetracyclines o 10.16 0.03 0.01 0.00 10.12 3.60 6.52
Amphenicols o 0.05 0.00 0.00 0.01 0.04 0.00 0.04
Amphenicols p 0.50 0.03 0.36 0.00 0.11 0.01 0.10
Narrow  spectrum penicillins o 0.04 0.00 0.00 0.04 0.00 0.00 0.00
Narrow  spectrum penicillins p 23.70 7.25 0.27 0.00 16.17 6.75 9.42
Other  penicillins o 5.13 0.00 0.04 0.26 4.83 1.31 3.52
Other  penicillins p 5.15 0.83 0.16 0.00 4.16 0.17 3.99
Cephalosporins 1/2 gen o 0.07 0.07 0.00 0.00 0.00 0.00 0.00
Cephalosporins 3/4 gen p 0.10 0.05 0.00 0.00 0.05 0.00 0.05
Trimethoprim/sulfonamides o 3.34 0.54 0.35 0.02 2.42 0.10 2.33
Trimethoprim/sulfonamides p 7.34 0.73 0.13 0.00 6.48 0.04 6.44
Macrolides o 15.48 0.00 0.03 0.20 15.25 4.88 10.37
Macrolides p 2.52 0.15 0.04 0.00 2.32 1.10 1.22
Fluoroquinolones o 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fluoroquinolones p 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other  quinolones o 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Others  (e.g. pleuromutilins) o, p 10.46 0.00 0.00 0.01 10.45 5.23 5.22
Combinations o 0.19 0.00 0.01 0.00 0.18 0.00 0.18
Combinations p 5.45 0.59 0.27 0.00 4.58 0.24 4.34
Total  115.01 11.55 2.36 0.77 100.34 31.56 68.78
a Excluding consumption of 0.124 tonnes active substance in game birds.
b Consumption in weaners below 30 kg is included in consumption sows/piglets, not in fattening pigs.
Some indications on species level seem to be accurate,
but that is only coincidental. The estimated overall aver-
age (

NADD) is quite accurate, but can only be interpreted
correctly if also the NADDs on species level are available.
If for example we exclude the use and the biomass of
the calves for veal and young beef production, the overall
average for the Netherlands strongly decreases from 13 to
10 ADDs, whereas the average for Denmark remains at the
level of 9 ADDs. In this example the overall average for NL
is nearly equal to the average for DK, due to the fact that the
weight of ‘dairy and other cattle’ in NL is more than twice
as high as the weight of these animals in DK, as shown in
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Table 6
Accuracy of model estimations; expressed as error percentage of true NADD value per species (ε).
Estimation A. All animals Estimation B. Meat animals Estimation C. Meat animals Estimation C. Dairy
and other cattle
NL DK NL DK NL DK NL DK
Pigs (total) −30% −34% 68% −34% 40% −45% n.r. n.r.
Sows/piglets −31% −53% 67% −53% 39% −61% n.r. n.r.
Fattening pigs −30% 2% 69% 2% 40% −15% n.r. n.r.
Poultry −55% 175% 8% 175% −10% 129% n.r. n.r.
Veal  calves young beef −80% 52% −51% 52% −59% 27% n.r. n.r.
Dairy  and other cattle 202% 258% n.r. n.r. n.r. n.r. 44% 321%
Average All animalsa 7% 8% 156% 8% 113% −10% −49% 26%
Average Meat animalsb −49% −32% 22% −32% 2% −43% n.r. n.r.
Findings expressed in bold face are considered ‘accurate’, i.e. error percentage below 30%. n.r. means not relevant.
a Overall average, based on true NADD values per species, for all species.
b Overall average, based on true NADD values per species, for the meat producing species (pigs, poultry, veal calves).
Fig. 1. Model estimations of antibiotic use in 2010, expressed in NADD,
based on total sales data and using different formulas. In formula EA the
ADDs were calculated by dividing the total sales by the total live treatment
weight of the livestock and an overall average dosage. In formula EB the
total sales were divided by the live treatment weight of only animals for
meat production and the average dosage for those animals. In formula EC o
the orally administered sales were divided by the live treatment weight of
animals for meat production and the average dosage for that category of
animals. In formula EC p the parenterally administered sales were divided
by  the live treatment weight of the dairy and other cattle, and the average
dosage for that category of animals. Meat animals comprises Category A
in  Table 3; Dairy and other cattle (except calves for veal and young beef
production) is Category B.
Table 3. Thus, the relatively low use and high biomass of
dairy and other cattle has much more impact on the over-
all average for the Netherlands, than the higher use levels
in pigs and poultry. In contrast, in Denmark cattle and pigs
contribute more equally to the total animal biomass.
In model calculation EC, the key assumption was that
the animals for meat production only get orally adminis-
tered antimicrobials. From the comparison of the outcomes
of calculation EC, as shown in Fig. 1, and the outcomes in
Fig. 2, it can be concluded that calculation EC leads to a
substantial underestimation of the use in pigs, the major
category of animals for meat production in Denmark (only
8 ADDs in model calculation EC oral, 14 ADDs based on use
data per species), and an overestimation of the use in dairy
and other cattle. Apparently, in Denmark the animals for
meat production receive more antimicrobials by parenteral
administration than in the Netherlands. A dosage for oral
use, expressed in mg  per kg per day, is usually higher than
Fig. 2. Antibiotic use in 2010, expressed in NADD, based on collected
data per species. Two averages, for respectively all species and only meat
producing species, are included in this ﬁgure, for comparison with the
outcomes of the model estimates in Fig. 1. The average All animals is
the  weight-weighted average of the true NADD values per species, for
all  species. The average Meat animals is the weight-weighted average of
the true NADD values per species, for the meat producing species (pigs,
poultry, veal calves).
the dosage for parenteral use. This difference in administra-
tion routes applied in Denmark versus the Netherlands also
contributes to the overall difference between the countries,
when measuring in mg  per kg.
4.2. Method to calculate the level of exposure
From a theoretical point of view, the best way to quan-
tify exposure to antimicrobial agents in a population is
to closely monitor the applied treatment of individual
animals, or at least of individual farms, and relate this
to the total population at risk. This method requires a
very detailed (preferably automated) registration of drug
application, or prescription, respectively, on every farm.
Some countries already installed such centralized sys-
tems for drug monitoring, like Denmark (on prescription
level), other countries are in the process of installing it
(Norway, the Netherlands and Belgium for instance). Addi-
tional advantages of registration on all individual farms
are the possibility of benchmarking and interventions by
a supervisory body. A cheaper and less ambitious, but also
useful option is the monitoring of total sales on national
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level, combined with a representative sample survey for
the collection of use data per animal species, as it was  done
in the Netherlands since 2004.
The main challenges for the estimation of antimicro-
bial exposure are deﬁning an accurate way of quantifying
the amount of antimicrobial agents used, and deﬁning the
size of the population ‘at risk’ of being treated. From an
epidemiological perspective, it would be ideal to com-
pare the amounts used with the ‘population at risk’,
being the live biomass at a given point. This is compara-
ble with the methods used in human medicine: use per
1000 inhabitants-days, assuming that the average size per
human is constant. The use in dosages per kg live biomass at
risk represents the selection pressure, which is exerted on
the live animals during their lifespan. Simple comparisons
using total sales data automatically ignore the impact of
differences in age (size) and composition of the animal pop-
ulation at risk, and the impact of differences in the average
dosage (‘potency’) of the used antimicrobials. The NADD is
a useful proxy for the number of daily doses or treatment
days per animal per year. However, the actual exposure
might still differ from the calculated levels, because actual
treatment weights and applied dosages might be different
from the assumptions.
The outcome of model calculation EA reveals the impact
of the difference in average dosage of the used antimicro-
bials: comparing the sales in mg  per kg treatable weight,
respectively 213 mg  per kg in NL and 101 mg  per kg in DK,
indicates an extremely high use level in the Netherlands,
more than twice the level of Denmark. However, after
adjustment for average potency, the remaining overall dif-
ference in exposure is approximately 40%: respectively 13
treatment days in NL, 9 in DK (model calculation EA, average
for All animals). The average potency of the used antimicro-
bials is substantially higher in Denmark, since macrolides
and pleuromutilins, which are administered in low doses,
are both almost equally used as tetracyclines, whereas in
the Netherlands a much higher proportion of the use is
tetracyclines. In model calculation EB (average for Meat ani-
mals), the use level in the animals for meat production is
overestimated, because of the assumption of zero use in
dairy and other cattle.
Still, the method of dividing an amount of active com-
pound consumed in a population by a deﬁned daily dosage
(ADDkg) could induce a false estimation of the num-
ber of days of treatment realized, because often the real
prescribed daily dosage differs from the deﬁned dosage
(Chauvin et al., 2002). For that reason, WHO  states that
drug consumption data presented in DDDs only gives a
rough estimate of consumption and not an exact picture of
actual consumption (WHO, 2012). For instance, it is impos-
sible to distinct application of high doses during a short
period of time from application of low doses during a longer
period of time, though the selection pressure derived from
those strategies will obviously differ. Pardon et al. (2012)
compared authorized doses (ADDs) with applied doses
(UDDs) and came to the conclusion that veal calf produc-
ers in Belgium tended to closely follow the veterinarian’s
prescriptions, but also some overdosing and underdosing
was found. In the Netherlands, the poultry farms register
every day when medication is administered, resulting in a
number of treatment days per herd per production round.
Combining a method like that with the calculation of ADDs
would give the most detailed information.
However, calculation of ADDs enables researchers to
assess trends in drug use and to perform comparisons
between population groups. The deﬁned daily dosage
should be considered as a measure of quantity rather than
treatment days, but still is a much better measure of expo-
sure than measures in mg  active substance.
4.3. Explanations for differences in use
In the comparison of the two countries, the estimates
per animal species showed limited differences in use in
pigs and in dairy and other cattle, and very large differ-
ences in poultry and veal and young beef cattle (Fig. 2).
An analysis of the possible reasons for these substantial
differences was  no part of our study. The animal produc-
tion in Denmark might differ from the Netherlands in many
ways, e.g. infection pressure (number of animals per km2),
climate, robustness of animals, scale and quality of hous-
ing systems (van der Fels-Klerx et al., 2011) and/or feed
quality. Furthermore, there might be relevant differences
in legislation, regarding both antimicrobials and feed addi-
tives, in farming and veterinary practices (Hughes et al.,
2012; Chauvin et al., 2002) and also in awareness, skills and
knowledge among farmers and veterinarians. The large dif-
ference in use in the veal and beef production might relate
to the fact that male calves Denmark are mainly used for
“young beef” production, whereas the Netherlands mainly
produces veal calves. Also, the Netherlands receive calves
from many other countries for fattening, thus exposing the
young calves to more stressful conditions, including long
transports and mixing of calves from many origins. Finally,
for an adequate evaluation of the (differences in) use levels
information from several sources is needed, for example
about disease outbreaks.
4.4. Assumptions applied to estimate antimicrobial use
in different categories of animals
The main assumption in model calculation EA was that
the exposure level to antimicrobial agents is evenly dis-
tributed to all animals. This results in a very straightforward
estimation of the overall average exposure. However, the
validity of this estimated exposure is low, because sub-
stantial differences in use levels among species are to be
expected.
The assumption in model calculation EB that the use in
dairy and other cattle is negligible, may  lead to a substantial
overestimation of the number of ADDs for the animals for
meat production, especially in countries with a relatively
large dairy cattle population.
For model calculation EC, the differentiation between
oral and parenteral administration is crucial. It is expected
that future sales data in the European ESVAC project will
be requested on package level, and therefore the admin-
istration route will be known. The accuracy of estimates
from this approach depends on the therapeutic practices
in the individual country. The remaining challenge will be
an accurate assignment of the sales to the different species.
N. Bondt et al. / Preventive Veterinary Medicine 108 (2013) 10– 20 19
Obviously, the discussed approaches strongly inﬂuence
the outcomes of the model estimates for the exposure
to antimicrobial agents. It should be stressed that the
assessed calculations are only three of many possible ways
to estimate an exposure level. Furthermore, the differences
among species appear to be much more important than the
overall difference between the two countries. This means
that it is impossible to gain insight into true exposure lev-
els without reliable information about the use per animal
species.
4.5. Census data versus production data
In our calculations the sales of antimicrobial agents dur-
ing a certain year were related to the size of the live animal
population in that same year. The application of census data
is the clearest and most direct way to determine the size
of the population at risk. However, it includes an estima-
tion of the average treatment weight in growing animals
(also within age group for census data). Alternatively, the
average live weight, estimated from growth curves could
be applied. Although often just based on sample surveys,
census data represent the size of the population averagely
present during a year. It is meaningless to determine the
size of the population at risk by adding up the live weight of
dairy cows and sows and the weight of slaughtered animals,
since slaughterweight severely overestimates the denom-
inator (in biomass-year) for growing animals, particularly
when these are slaughtered before one year of age, and
more so the younger the animal is at slaughter; addition-
ally, fattening and slaughter might take place in different
countries. However, such a theoretical unit for the size of
the animal population could still be suitable to show trends
in the sales within a country, but certainly not for estimat-
ing true exposure or comparing the use among countries.
5. Conclusions
This paper explores the possibilities of making mean-
ingful comparisons of the veterinary use of antimicrobial
agents among countries, based on national total sales data
and animal census data. It is argued that for adequate
country comparisons both the average dosage of the used
antimicrobial agents (‘potency indicator’) and the differ-
ences in farm animal demographics have to be taken into
account.
Although our analysis seems to conﬁrm the ﬁnding of
Grave et al. (2010)7 that the level of antimicrobial use in
Denmark is lower than in the Netherlands, it is obvious
that a straightforward model calculation based on total
sales data and expressed in mg  per kg biomass (or PCU),
indicating a 110% higher use in the Netherlands compared
to Denmark, strongly overestimates the true difference
7 The outcome of these calculations cannot directly be compared to the
results of the study of Grave et al. (2010), because Grave et al. did not adjust
for  differences in potency of antimicrobial agents and did not express the
size of the livestock in the live weight of the animals averagely present
during the year, but in an adding up of the produced weight of slaughtered
animals and the live weight of dairy cows. Besides, Grave et al. (2010)
reported about the year 2007, whereas this paper is about 2010.
in use. This is in spite of the fact that the farm animal
demographics in these two countries seem to be quite sim-
ilar. The overestimation will be even more severe when
comparisons are made between countries with substan-
tial differences in animal demographics, e.g. countries with
mostly dairy cattle compared to countries with mostly
animals for meat production. Taking the large differ-
ence in ‘potency indicator’ (average dosage) into account,
the overall average use in the Netherlands turns out to
be approximately 40% higher than the use in Denmark,
according to model estimate EA. An analysis on species level
reveals that the differences in use among animal species
and production types were much higher than the computed
overall average difference between the two  countries.
This paper clearly shows that total national sales data
are not suitable for country comparisons of selection pres-
sure on species level. All of the assessed model estimates
are strongly inﬂuenced by animal demographics and vet-
erinary practices, and therefore unsuitable to indicate the
true levels of exposure in the different animal species.
Every simple country comparison based only on total sales
ﬁgures entails the risk of serious misinterpretations, espe-
cially if expressed in mg  per kg. This also applies to the
comparison of countries that are generally considered to
be similar in animal demographics, like Denmark and the
Netherlands. For meaningful and accurate country com-
parisons of exposure levels, it is vital to have reliable
information about the use per animal species.
Reliable insight into the true levels of exposure is
an important step towards assessing the risks of emer-
gence and spread of antimicrobial resistance. However,
a solid risk assessment requires additional information,
for instance about the compliance to authorized dosing
regimens and other parameters indicating the level of
prudence, concerning the prescription and application of
antimicrobial agents in food producing animals (‘antibiotic
stewardship’).
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